Evidence map›Paper›PMID 34783659›Full record

ArticleJMIR research protocols2021

Discovery of Arthritis in Psoriasis Patients for Early Rheumatological Referral (DAPPER): Protocol for a Longitudinal Observational Study.

Tamara W van Hal, Juul Mpa Van den Reek, Hans Mm Groenewoud, Marcel C Pasch, Frank Hj Van den Hoogen, Mark H Wenink, Elke Mgj De Jong

Open access · goldAbstract read
In one paragraph

Article in JMIR research protocols, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Tamara W van HalDepartment of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands.ORCID https://orcid.org/0000-0001-9467-1814
Juul Mpa Van den ReekDepartment of Dermatology, Radboud University Medical Center, Nijmegen, Netherlands.ORCID https://orcid.org/0000-0002-3642-2673
Hans Mm GroenewoudRadboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, Netherlands.ORCID https://orcid.org/0000-0002-4974-150X
Marcel C PaschDepartment of Dermatology, Radboud University Medical Center, Nijmegen, Netherlands.ORCID https://orcid.org/0000-0001-8169-9607
Frank Hj Van den HoogenDepartment of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands.ORCID https://orcid.org/0000-0003-1044-015X
Mark H WeninkDepartment of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands.ORCID https://orcid.org/0000-0002-0088-4155
Elke Mgj De JongDepartment of Dermatology, Radboud University Medical Center, Nijmegen, Netherlands.ORCID https://orcid.org/0000-0003-3872-5704
Radboud University Nijmegen · NLSint Maartenskliniek · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOne in three patients with psoriasis will develop psoriatic arthritis (PsA). If left untreated, this can lead to pain, impaired function, and irreversible joint damage. Timely recognition and referral to a rheumatologist are therefore key. However, current methods used to screen patients with psoriasis for those who might benefit from referral to a rheumatologist are not performing well enough.

objectiveThe Discovery of Arthritis in Psoriasis Patients for Early Rheumatological Referral (DAPPER) study is designed to determine the prevalence of PsA in a psoriasis population and to find parameters that can be used to develop a new or enhance an existing instrument for a rheumatological referral.

methodsDAPPER is a longitudinal observational study with a 1-year follow-up. Patients with psoriasis (N=300) who are treated at an outpatient dermatological clinic will be screened extensively for signs and symptoms of PsA by a trained rheumatologist. If there is clinical suspicion of PsA and the patient is not yet treated by a rheumatologist, referral to the Department of Rheumatology will follow for confirmation of the diagnosis and further care. After 1 year, data on changes in quality of life and PsA and psoriasis disease activity will be collected from the referred patients. The screening visit will be used to gather demographical and medical data, which can later be used to develop the aforementioned screening instrument.

resultsInclusion started in June 2019 and finished in June 2021. Follow-up with newly discovered patients with PsA is ongoing.

conclusionsThe DAPPER study is specifically designed to improve the detection of existing PsA in a dermatologic outpatient setting. Although internal validity will be tested, external validity will have to be checked using a second validation cohort. To predict the development of PsA in the future, longitudinal/prospective data collection is required and will be performed in a follow-up study (DAPPER-i).

trial registrationDutch Trial Register NTR7604; https://www.trialregister.nl/trial/7397. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/31647.

Indexed as

psoriasispsoriatic arthritisscreening

Identifiers

PMID34783659
PMCPMC8663491
OpenAlexW3214644446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.